Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Federal Trade Commission vote on Aug. 31 consent agreement allowing Roche to acquire 60% of Genentech was 3-2, with Commissioners Terry Calvani and Deborah Owen dissenting. Calvani said he would have voted yes if agreement, as recommended by FTC staff, "also provided relief" from potential anticompetitive effect of "gamma interferon and recombinant DNA products under development by Roche." Agreement calls for Genentech to divest interest in vitamin C and Roche to license CD4 in the U.S. and divest human growth hormone-promoting factor ("The Pink Sheet" Sept. 3, T&G-1). Consent agreement appeared in Sept. 17 Federal Register for 60-day comment period.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts